

Ileana L Piñón

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4782926/publications.pdf>

Version: 2024-02-01

129
papers

13,787
citations

81434

41
h-index

24511

114
g-index

131
all docs

131
docs citations

131
times ranked

13525
citing authors

#	ARTICLE	IF	CITATIONS
1	Do PRO Measures Function the Same Way for all Individuals With Heart Failure?. Journal of Cardiac Failure, 2023, 29, 210-216.	0.7	2
2	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	0.8	11
3	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. Journal of Cardiac Failure, 2022, 28, 835-844.	0.7	1
4	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
5	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	2.9	41
6	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation, 2022, 145, 819-828.	1.6	7
7	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	0.7	23
8	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress in Cardiovascular Diseases, 2022, , .	1.6	1
9	Time to Re-Examine Maternity Leave in Cardiology Training. Journal of the American College of Cardiology, 2022, 79, 2127-2128.	1.2	0
10	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. Circulation, 2022, 146, 80-90.	1.6	32
11	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 127-136.	1.9	47
12	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	1.9	27
13	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	1.0	114
14	Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure. Journal of Cardiovascular Translational Research, 2021, 14, 984-991.	1.1	2
15	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019712.	1.6	6
16	Association Between Angiotensin Receptorâ€“Nepriylsin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008410.	1.6	27
17	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182.	1.6	28
18	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. JACC: Heart Failure, 2021, 9, 471-481.	1.9	38

#	ARTICLE	IF	CITATIONS
19	SGLT2 inhibitors: the story continues to unfold. <i>European Heart Journal</i> , 2021, , .	1.0	3
20	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	13.9	2,143
21	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	1.6	12
22	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , 2021, , .	1.4	3
23	Race and Ethnicity in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2589-2598.	1.2	27
24	Managing the economic challenges in the treatment of heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 612.	0.7	4
25	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	1.6	18
26	Effect of patiomer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 656-661.	1.6	4
27	Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020, 22, 2018-2025.	2.9	21
28	The New Kids on the Block: Don't Delay. <i>Journal of Cardiac Failure</i> , 2020, 26, 811-812.	0.7	0
29	One Small Step . . . <i>JACC: CardioOncology</i> , 2020, 2, 596-598.	1.7	0
30	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e006946.	1.6	28
31	Acute Kidney Injury: To Be or Not to Be: That Is the Question: It's the Company It Keeps. <i>American Journal of Nephrology</i> , 2020, 51, 169-171.	1.4	0
32	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	3.0	74
33	A "Silent" Passenger Speaks Loudly. <i>JACC: Heart Failure</i> , 2020, 8, 289-290.	1.9	0
34	How Long Will We Play the Ostrich Game?. <i>Circulation: Heart Failure</i> , 2020, 13, e007043.	1.6	0
35	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	2.9	205
36	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1085.	3.8	403

#	ARTICLE	IF	CITATIONS
37	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1205-1217.	1.2	54
38	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2019, 7, 878-887.	1.9	37
39	Burden of medical comorbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 373-381.	2.9	12
40	Sex Differences in Heart Failure—Female Representation in Heart Failure Studies. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	1
41	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
42	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-T predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	2.9	36
43	Stress-Induced Cardiomyopathy. <i>Heart Failure Clinics</i> , 2019, 15, 41-53.	1.0	18
44	Heart Failure Postdischarge Clinic: A Pharmacist-led Approach to Reduce Readmissions. <i>Current Problems in Cardiology</i> , 2019, 44, 100407.	1.1	15
45	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , 2018, 199, 97-104.	1.2	9
46	Sex differences in heart failure. <i>Clinical Cardiology</i> , 2018, 41, 211-216.	0.7	98
47	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). <i>American Heart Journal</i> , 2018, 199, 130-136.	1.2	71
48	Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. <i>Circulation</i> , 2018, 137, 771-780.	1.6	34
49	Government continues to have an important role in promoting cardiovascular health. <i>American Heart Journal</i> , 2018, 198, 160-165.	1.2	6
50	Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. <i>Europace</i> , 2018, 20, f211-f216.	0.7	11
51	If It Is Not Health Care Access or Insurance Coverage, Then Why Do Racial Disparities Persist?. <i>JACC: Heart Failure</i> , 2018, 6, 421-423.	1.9	1
52	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2551-2562.	1.2	20
53	Improving Provider Adherence to Guideline Recommendations in Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 350-356.	1.3	3
54	Managing the Economic Challenges in the Treatment of Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 476-483.	1.6	4

#	ARTICLE	IF	CITATIONS
55	The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017. Circulation: Heart Failure, 2018, 11, e004957.	1.6	8
56	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. American Journal of Cardiology, 2018, 122, 999-1007.	0.7	5
57	Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004643.	0.9	0
58	Atrial fibrillation inducibility during cavo-tricuspid isthmus dependent atrial flutter ablation for the prediction of clinical atrial fibrillation. International Journal of Cardiology, 2017, 240, 246-250.	0.8	7
59	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. American Heart Journal, 2017, 186, 130-138.	1.2	27
60	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1683-1691.	1.2	45
61	Effect of Natriuretic Peptide—Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	3.8	386
62	Heart Failure Transitions of Care: A Pharmacist-Led Post-Discharge Pilot Experience. Progress in Cardiovascular Diseases, 2017, 60, 249-258.	1.6	30
63	Implementation of a Patient Navigator Program to Reduce 30-day Heart Failure Readmission Rate. Progress in Cardiovascular Diseases, 2017, 60, 259-266.	1.6	47
64	Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure, 2017, 4, 499-506.	1.4	42
65	Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from) Tj ETQq1 1 0.784314 rgBT /Over 0.7	0.7	0
66	Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities — a National Heart, Lung, and Blood Institute workshop report. BMC Proceedings, 2017, 11, 11.	1.8	22
67	Heart Failure Management and Development of Heart Failure Programs. , 2017, , 783-803.		0
68	Statins and Exercise Training Response in Heart Failure Patients. JACC: Heart Failure, 2016, 4, 617-624.	1.9	9
69	Donor Troponin and Survival After Cardiac Transplantation. Circulation: Heart Failure, 2016, 9, .	1.6	33
70	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	1.2	86
71	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). American Journal of Cardiology, 2016, 118, 1211-1216.	0.7	11
72	Frailty Assessment in Advanced Heart Failure. Journal of Cardiac Failure, 2016, 22, 840-844.	0.7	51

#	ARTICLE	IF	CITATIONS
73	Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 780-789.	1.2	157
74	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 165-175.	1.9	120
75	Microvascular obstruction detected by cardiac MRI after AMI for the prediction of LV remodeling and MACE: A meta-analysis of prospective trials. <i>International Journal of Cardiology</i> , 2016, 202, 344-348.	0.8	16
76	Improving Quality of Cardiac Care: A Global Mandate. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 924-927.	0.4	2
77	Sex Differences in Device Therapy for Heart Failure: Utilization, Outcomes, and Adverse Events. <i>Journal of Women's Health</i> , 2015, 24, 261-271.	1.5	25
78	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2015, 8, 1044-1051.	1.6	52
79	Non-invasive assessment of low risk acute chest pain in the emergency department: A comparative meta-analysis of prospective studies. <i>International Journal of Cardiology</i> , 2015, 187, 565-580.	0.8	24
80	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 709-716.	1.6	9
81	Authorship in a multicenter clinical trial: The Heart Failure—A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) Scoring System Results. <i>American Heart Journal</i> , 2015, 169, 457-463.e6.	1.2	13
82	The Potential Role of Natriuretic Peptide—Guided Management for Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 233-239.	0.7	16
83	Exercise Training and Pacing Status in Patients With Heart Failure: Results From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2015, 21, 60-67.	0.7	32
84	Cardiac Resynchronization Therapy in Women. <i>JAMA Internal Medicine</i> , 2014, 174, 1340.	2.6	168
85	Relationship Between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2014, 20, 38-44.	0.7	28
86	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. <i>American Heart Journal</i> , 2014, 167, 193-202.e1.	1.2	50
87	Clinical Implications of Chronic Heart Failure Phenotypes Defined by Cluster Analysis. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1765-1774.	1.2	197
88	From Acute Decompensated to Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 1923-1929.	0.7	12
89	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	1.9	43
90	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	1.9	106

#	ARTICLE	IF	CITATIONS
91	Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT. <i>Journal of the American College of Cardiology</i> , 2014, 64, 887-894.	1.2	85
92	Effects of Exercise Training on Outcomes in Women With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 180-186.	1.9	40
93	Coronary Computed Tomography Angiography for the Detection of Cardiac Allograft Vasculopathy. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1992-2004.	1.2	122
94	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014, 175, 30-37.	0.8	37
95	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 260-268.	1.9	104
96	Abstract P320: Discordance of Framingham Risk Score and Reynolds Risk Score to Global Vascular Risk Score: Results from the Hispanic Community Health Study/Study of Latinos. <i>Circulation</i> , 2014, 129, .	1.6	0
97	The STICH Trial (Surgical Treatment for Ischemic Heart Failure). <i>JACC: Heart Failure</i> , 2013, 1, 400-408.	1.9	82
98	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise Training (HF-ACTION). <i>American Heart Journal</i> , 2013, 166, 488-495.e1.	1.2	29
99	Left Bundle Branch Block Predicts Better Survival in Women Than Men Receiving Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2013, 1, 237-244.	1.9	45
100	Forecasting the Impact of Heart Failure in the United States. <i>Circulation: Heart Failure</i> , 2013, 6, 606-619.	1.6	2,206
101	A Randomized Controlled Trial of High-Dose Vitamin D 3 in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 84-90.	1.9	77
102	Hospital Strategies Associated With 30-Day Readmission Rates for Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 444-450.	0.9	293
103	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 167-175.	1.6	48
104	Trends In Heart Failure Hospitalizations. <i>Current Heart Failure Reports</i> , 2012, 9, 346-353.	1.3	26
105	Heart Failure in Women. <i>Clinical Cardiology</i> , 2012, 35, 172-177.	0.7	34
106	Quality Improvement in Heart Failure: A Randomized Educational Intervention to Change Provider Behavior. <i>Congestive Heart Failure</i> , 2012, 18, 245-253.	2.0	7
107	Behavioral Intervention, Nutrition, and Exercise Trials in Heart Failure. <i>Heart Failure Clinics</i> , 2011, 7, 467-479.	1.0	1
108	Cardiovascular Disease in Women. <i>Cardiology in Review</i> , 2011, 19, 71-75.	0.6	14

#	ARTICLE	IF	CITATIONS
109	Disparities in Women with Heart Failure. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 261-265.	0.8	2
110	Transitions of Care in Heart Failure: The Case for Comparative Effectiveness Research. <i>Current Heart Failure Reports</i> , 2011, 8, 81-83.	1.3	0
111	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction in Women. <i>Archives of Internal Medicine</i> , 2011, 171, 1088-9.	4.3	0
112	Cardiac Rehabilitation in Heart Failure: A Brief Review and Recommendations. <i>Current Cardiology Reports</i> , 2010, 12, 223-229.	1.3	12
113	Effects of Exercise Training on Health Status in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1451.	3.8	631
114	Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1439.	3.8	1,694
115	Baseline differences in the HF-ACTION trial by sex. <i>American Heart Journal</i> , 2009, 158, S16-S23.	1.2	40
116	Heart Failure in Women. <i>Journal of the American College of Cardiology</i> , 2009, 54, 491-498.	1.2	172
117	Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): Design and rationale. <i>American Heart Journal</i> , 2007, 153, 201-211.	1.2	206
118	AACVPR/ACC/AHA 2007 Performance Measures on Cardiac Rehabilitation for Referral to and Delivery of Cardiac Rehabilitation/Secondary Prevention Services. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1400-1433.	1.2	258
119	Sleep symptoms and clinical markers of illness in patients with heart failure. <i>Sleep and Breathing</i> , 2005, 9, 127-133.	0.9	35
120	ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 1853-1887.	1.6	221
121	Exercise and Heart Failure. <i>Circulation</i> , 2003, 107, 1210-1225.	1.6	890
122	Heart Failure in Women. <i>Cardiology in Review</i> , 2003, 11, 337-344.	0.6	17
123	The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 319-324.	2.0	1
124	Evaluating Quality of Care for Patients With Heart Failure. <i>Circulation</i> , 2000, 101, E122-40.	1.6	130
125	A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitoring. <i>American Heart Journal</i> , 2000, 139, 543-548.	1.2	136
126	Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. <i>American Journal of Cardiology</i> , 1999, 84, 894-899.	0.7	23

#	ARTICLE	IF	CITATIONS
127	Exercise and Heart Failure. Chest, 1996, 110, 1317-1327.	0.4	25
128	Criteria for use of intravenous milrinone in adult inpatients. American Journal of Health-System Pharmacy, 1995, 52, 1918-1919.	0.5	0
129	Impedance Cardiography. , 0, , 77-87.		0